dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.creatorBeltrame, Ana Lucia
dc.creatorSerafini, Paulo
dc.creatorMotta, Eduardo L. A. [UNIFESP]
dc.creatorSoares Junior, Jose Maria [UNIFESP]
dc.creatorBaracat, Edmund C.
dc.date.accessioned2016-01-24T14:31:23Z
dc.date.accessioned2023-09-04T18:31:01Z
dc.date.available2016-01-24T14:31:23Z
dc.date.available2023-09-04T18:31:01Z
dc.date.created2016-01-24T14:31:23Z
dc.date.issued2013-03-01
dc.identifierGynecological Endocrinology. New York: Informa Healthcare, v. 29, n. 3, p. 201-204, 2013.
dc.identifier0951-3590
dc.identifierhttp://repositorio.unifesp.br/handle/11600/36073
dc.identifier10.3109/09513590.2012.736554
dc.identifierWOS:000315166800004
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8615623
dc.description.abstractThe aim of this study was to evaluate the effects of bromocriptine on vascular endothelial growth factor (VEGF) levels in serum, kidney function and ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Twenty-eight women were randomly divided into two groups and were administered daily oral capsules for 14 days, starting on the day of human chorionic gonadotropin (hCG) administration. Group A received 2.0 mg of folic acid, whereas Group B was given 2.5 mg of bromocriptine. Physical exams, pelvic ultrasounds and laboratory evaluations were performed on the day of hCG administration and again 7 days later. No differences in ovarian hyperstimulation syndrome, urine volume, creatinine clearance, urine sodium concentration or serum VEGF levels were found between the two groups. Thus, these results indicate that bromocriptine does not affect blood levels of VEGF, kidney function or the incidence of ovarian hyperstimulation syndrome in high-risk patients subjected to in vitro fertilization.
dc.languageeng
dc.publisherInforma Healthcare
dc.relationGynecological Endocrinology
dc.rightshttp://informahealthcare.com/userimages/ContentEditor/1255620309227/Copyright_And_Permissions.pdf
dc.rightsAcesso restrito
dc.subjectBromocriptine
dc.subjectfertilization
dc.subjecthyperstimulation syndrome
dc.subjectkidney function
dc.subjectVEGF
dc.titleThe effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study
dc.typeArtigo


Este ítem pertenece a la siguiente institución